|
Development and Evaluation of Febuxostat Sublingual Tablet Formulation
|
|
| Author:
|
PRASHANT BHIDE, NASHOMA FERNANDES, JUBEKA DCUNHA
|
| Abstract:
|
Febuxostat drug is recently developed for treatment of gout and classified under BCS class II. For treatment of gout, per-oral route is preferred route of administration, but first pass effect and poor bioavailability limits its application. To overcome these limitations efforts were made to enhance bioavailability of drug via development of sublingual tablet. The formulation was developed by direct compression method, where superdisintegrants like crospovidone, Kyron T-114®, sodium starch glycolate, croscarmellose sodium, Tulsion 339® and Indion 234® were used to enhance solubility and drug release rate. The tablets were evaluated for hardness, thickness, friability, weight variation, drug content, wetting time, in-vitro disintegration time, water absorption ratio and in-vitro dissolution studies. It was concluded that sublingual tablet containing Kyron T-114® and crospovidone showed the highest release (95.37%) at the end of 8 minutes. The optimized batch was subjected for accelerated stability studies. No change in physicochemical properties as well as in drug content and in-vitro release studies was observed.
|
| Keyword:
|
Febuxostat, gout, sublingual, superdisintegrants, solubility
|
| EOI:
|
-
|
| DOI:
|
-
|
| Download:
|
Request For Article
|
|
|